Galmed Pharmaceuticals Ltd expected to post a loss of 38  cents a share - Earnings Preview

Eocene

11/05/2021 14:30

* Galmed Pharmaceuticals Ltd  GLMD.OQ   GLMD.O  is expected
to show a no change in quarterly revenue when it reports
results on May 13 .
​* Refinitiv's mean analyst estimate for Galmed Pharmaceuticals
Ltd is for a loss of 38 cents per share. For the same quarter
last year, the company reported a loss of 29 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $14​, about 83.2% above​ its last closing
price of $2.35. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.35       -0.36      -0.48     Missed  -31.9
 Sep. 30 2020  -0.29       -0.30      -0.32     Missed  -6.7
 Jun. 30 2020  -0.31       -0.32      -0.26     Beat    18.4​
 Mar. 31 2020  -0.35       -0.37      -0.29     Beat    20.8
 Dec.          -0.27​      -0.34      -0.39     Missed  -13.2​
 31​ 2019​                                              
 Sep. 30 2019  -0.29       -0.29      -0.21     Beat    27.9​
 Jun. 30 2019  -0.21       -0.22      -0.20     Beat    9.5
 Mar. 31 2019  -0.20       -0.20      -0.17     Beat    15.5
 This summary was machine generated May 11 at 13:30 GMT.  All
figures in US dollars unless otherwise stated